Abstract
Allergic rhinitis（AR） is a chronic inflammation of nasal mucosa mediated by IgE, which prevalence is increasing year by year. Allergen immunotherapy（AIT） has been proved to be effective in the treatment of AR. Patients can usually achieve satisfactory clinical remission after the standard course of treatment. At present, sIgE/tIgE is mainly used to evaluate the severity of allergy in patients with AR before immunotherapy, but there is no recognized biomarker for evaluating the efficacy of AIT. Based on the mechanism that immune cells participate in the formation of immune tolerance during AIT, this paper reviews the latest progress of immune cell markers in allergic rhinitis for the evaluation of the efficacy of AIT in recent years, in order to provide a more comprehensive evaluation basis for AR patients during immunotherapy.